Anna Tinker
Anna Tinker
BC Cancer Agency, Peter McCallum Cancer Centre
Verified email at bccancer.bc.ca
TitleCited byYear
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
RW Tothill, AV Tinker, J George, R Brown, SB Fox, S Lade, DS Johnson, ...
Clinical cancer research 14 (16), 5198-5208, 2008
10152008
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ...
New England Journal of Medicine 375 (22), 2154-2164, 2016
8202016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ...
The lancet oncology 18 (1), 75-87, 2017
4602017
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
W Sieh, M Köbel, TA Longacre, DD Bowtell, A DeFazio, MT Goodman, ...
The lancet oncology 14 (9), 853-862, 2013
2442013
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
B Clarke, AV Tinker, CH Lee, S Subramanian, M Van De Rijn, D Turbin, ...
Modern Pathology 22 (3), 393, 2009
2232009
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas
D Etemadmoghadam, A Defazio, R Beroukhim, C Mermel, J George, ...
Clinical cancer research 15 (4), 1417-1427, 2009
2142009
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas
MS Anglesio, S Kommoss, MC Tolcher, B Clarke, L Galletta, H Porter, ...
The Journal of pathology 229 (1), 111-120, 2013
1542013
Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers
JS Kwon, A Tinker, G Pansegrau, J McAlpine, M Housty, M McCullum, ...
Obstetrics & Gynecology 121 (1), 14-24, 2013
1522013
“Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?
A Davis, AV Tinker, M Friedlander
Gynecologic oncology 133 (3), 624-631, 2014
1482014
Clinical trials in recurrent ovarian cancer
M Friedlander, E Trimble, A Tinker, D Alberts, E Avall-Lundqvist, M Brady, ...
International Journal of Gynecologic Cancer 21 (4), 771-775, 2011
1332011
The role of the fallopian tube in ovarian cancer
AA Tone, S Salvador, SJ Finlayson, AV Tinker, JS Kwon, CH Lee, ...
Clin Adv Hematol Oncol 10 (5), 296-306, 2012
1192012
The challenges of gene expression microarrays for the study of human cancer
AV Tinker, A Boussioutas, DDL Bowtell
Cancer cell 9 (5), 333-339, 2006
1122006
Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors
MS Anglesio, JM Arnold, J George, AV Tinker, R Tothill, N Waddell, ...
Molecular cancer research 6 (11), 1678-1690, 2008
1052008
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND. 184
HJ Mackay, A Tinker, E Winquist, G Thomas, K Swenerton, A Oza, ...
Gynecologic oncology 116 (2), 163-167, 2010
1042010
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ...
Cancer discovery 7 (9), 984-998, 2017
982017
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ...
Nature genetics 49 (5), 680, 2017
972017
Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
S Böhm, A Faruqi, I Said, M Lockley, E Brockbank, A Jeyarajah, ...
Journal of Clinical Oncology 33 (22), 2457-2463, 2015
922015
Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.
IA McNeish, AM Oza, RL Coleman, CL Scott, GE Konecny, A Tinker, ...
Journal of Clinical Oncology 33 (15_suppl), 5508-5508, 2015
912015
Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation
PJ Hoskins, N Le, B Gilks, A Tinker, J Santos, F Wong, KD Swenerton
Journal of Clinical Oncology 30 (14), 1656-1662, 2012
832012
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials …
AV Tinker, S Ellard, S Welch, F Moens, G Allo, MS Tsao, J Squire, D Tu, ...
Gynecologic oncology 130 (2), 269-274, 2013
752013
The system can't perform the operation now. Try again later.
Articles 1–20